Evidence map›Paper›PMID 41887531›Full record

ArticleJournal of lipid research2026

Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background.

José A Inia, Leo H Zhang, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop-van Straalen, Marc Ditmarsch, Mathijs de Kleer, J Wouter Jukema, John J P Kastelein, Michael Szarek and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

José A IniaDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of Cardiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands. Electronic address: jose.inia@tno.nl.
Leo H ZhangDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of Cardiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands.
Nanda KeijzerDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Nicole WormsDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Anita van Nieuwkoop-van StraalenDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Marc DitmarschNewAmsterdam Pharma, Naarden, the Netherlands.
Mathijs de KleerNewAmsterdam Pharma, Naarden, the Netherlands.
J Wouter JukemaDepartment of Cardiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands; Netherlands Heart Institute, Utrecht, the Netherlands.
John J P KasteleinNewAmsterdam Pharma, Naarden, the Netherlands; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Michael SzarekCPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA; State University of New York, Downstate School of Public Health, Brooklyn, NY, USA.
Anita M van den HoekDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Geurt StokmanDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Elsbet J PietermanDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Hans M G PrincenDepartment of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The selective cholesteryl ester transfer protein (CETP) inhibitor obicetrapib is in clinical evaluation for dyslipidemia and cardiovascular risk reduction. This study investigated how obicetrapib alone and with ezetimibe reduces non-HDL-C, affects atherosclerotic lesion progression, and regression when added to background atorvastatin intervention. APOE∗3-Leiden.CETP mice received a Western-type diet (WTD) or this diet supplemented with obicetrapib, ezetimibe, or both. After 8 weeks, all interventions reduced non-HDL-C levels (obicetrapib: -53%; ezetimibe: -19%; combination: -75%). Obicetrapib mono and combination treatment blocked CETP activity (-99% and -98%), thereby increasing HDL-C levels (+286% and +256%). Very low-density lipoprotein (VLDL) cholesterol production was not affected, while obicetrapib and the combination with ezetimibe increased VLDL clearance (plasma half-life [

Indexed as

AtherosclerosisAtorvastatinEzetimibeLipoproteins, VLDLReceptors, LDLAnimalsAnticholesteremic AgentsCholesterol Ester Transfer ProteinsMaleMiceAnticholesteremic AgentsAtorvastatinCholesterol Ester Transfer ProteinsEzetimibeLipoproteins, VLDLReceptors, LDLatherosclerosisCETPezetimibeHDL cholesterolnon-HDL cholesterolobicetrapibregression

Identifiers

PMID41887531
PMCPMC13122311

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.